Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | RXRA | P19793 | 2/20 | 0.51 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.51 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | SLC5A1 | P13866 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 3/20 | 0.46 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3473656 | 0.91 | MAPT (0.64) | MAPTSMN1; SMN2RXRANR1H2NR1H3 | |
| SCHEMBL3473623 | 0.91 | MAPT (0.55) | MAPTSMN1; SMN2RXRANR1H2NR1H3 | |
| SCHEMBL3472395 | 0.91 | MAPT (0.54) | MAPTSMN1; SMN2RXRANR1H2NR1H3 | |
| SCHEMBL3474587 | 0.88 | RXRA (0.55) | MAPTSMN1; SMN2RXRANR1H2NR1H3 | |
| SCHEMBL3471324 | 0.88 | MAPT (0.59) | MAPTSMN1; SMN2RXRANR1H2NR1H3 | |
| SCHEMBL3470926 | 0.88 | MAPT (0.55) | MAPTSMN1; SMN2RXRANR1H2NR1H3 | |
| SCHEMBL3472322 | 0.88 | MAPT (0.55) | MAPTSMN1; SMN2RXRANR1H2NR1H3 | |
| SCHEMBL3471319 | 0.88 | MAPT (0.51) | MAPTSMN1; SMN2RXRANR1H2NR1H3 | |
| SCHEMBL3472847 | 0.87 | RXRA (0.54) | MAPTSMN1; SMN2RXRANR1H2NR1H3 | |
| SCHEMBL3472362 | 0.87 | RXRA (0.54) | MAPTSMN1; SMN2RXRANR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| EP-1910307-A1 | PYRAZOLE BASED LXR MODULATORS | Exelixis, Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007002559-A1 | PYRAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331295-A1 | MODULATORS OF LXR | NR1H2, NR1H3, NR1H4 | MAPT 4737/4885SMN1; SMN2 4666/4885RXRA 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.